Cargando…

Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin

IMPORTANCE: Despite great expense and little evidence supporting use over corticosteroids, prescriptions for repository corticotropin (H. P. Acthar Gel; Mallinckrodt Pharmaceuticals) have increased markedly. Aggressive sales tactics and payments from the manufacturer may influence prescribing behavi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartung, Daniel M., Johnston, Kirbee, Cohen, David M., Nguyen, Thuan, Deodhar, Atul, Bourdette, Dennis N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324413/ https://www.ncbi.nlm.nih.gov/pubmed/30646086 http://dx.doi.org/10.1001/jamanetworkopen.2018.0482

Ejemplares similares

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs
por: Perlis, Roy H., et al.
Publicado: (2016)

Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies
por: Patel, Aarat, et al.
Publicado: (2016)

Treatment of fibrillary glomerulonephritis with use of repository corticotropin injections
por: Maroz, Natallia, et al.
Publicado: (2018)

Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis
por: Rice, J. Bradford, et al.
Publicado: (2020)

Industry payments to physician journal editors
por: Wong, Victoria S. S., et al.
Publicado: (2019)

Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
por: Fischer, Peter A, et al.
Publicado: (2018)

Treatment of Noninfectious Retinal Vasculitis Using Subcutaneous Repository Corticotropin Injection
por: Anesi, Stephen D., et al.
Publicado: (2021)

Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
por: Mirsaeidi, Mehdi, et al.
Publicado: (2022)

Optimizing Physician Payment Models to Address Health System Priorities: Perspectives from Specialist Physicians
por: Ogundeji, Yewande Kofoworola, et al.
Publicado: (2021)

Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series
por: Brown, Alan N
Publicado: (2016)

Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis
por: Hunter, Samuel F, et al.
Publicado: (2021)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
por: Askanase, Anca D., et al.
Publicado: (2022)

Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation
por: Naseer, Muhammad Saad, et al.
Publicado: (2021)

Subcutaneous repository corticotropin gel for non-infectious panuveitis: Reappraisal of an old pharmacologic agent
por: Agarwal, Aniruddha, et al.
Publicado: (2016)

Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records
por: Chopra, Ishveen, et al.
Publicado: (2019)

Repository Corticotropin Injections Promote Clinical Remission and Regulatory T Cell Expansion in Membranous Nephropathy
por: Hartzell, Susan, et al.
Publicado: (2021)

US Nationwide Disclosure of Industry Payments and Public Trust in Physicians
por: Kanter, Genevieve P., et al.
Publicado: (2019)

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
por: Hartung, Daniel M., et al.
Publicado: (2015)

H.P. Acthar Gel (repository corticotropin injection) treatment of patients with multiple sclerosis and diabetes
por: Kutz, Christen
Publicado: (2016)

Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone
por: Lal, Ritu, et al.
Publicado: (2015)

Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis
por: Ho-Mahler, Nancy, et al.
Publicado: (2020)

Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2022)

Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis
por: Bindra, Jas, et al.
Publicado: (2021)

Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action
por: Gillis, Theresa, et al.
Publicado: (2017)

Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data
por: Sharma, Manvi, et al.
Publicado: (2018)

Impact of the Affordable Care Act's Physician Payments Sunshine Act on branded statin prescribing
por: Li, Jing, et al.
Publicado: (2022)

Association of Specialist Physician Payment Model With Visit Frequency, Quality, and Costs of Care for People With Chronic Disease
por: Quinn, Amity E., et al.
Publicado: (2019)

Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab
por: Knight, Tyler, et al.
Publicado: (2017)

A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse
por: Kaplan, Jeffrey, et al.
Publicado: (2020)

Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
por: Fleischmann, Roy, et al.
Publicado: (2022)

Association Between Open Payments–Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US
por: Nguyen, Andrew M., et al.
Publicado: (2022)

Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States
por: Nelson, Winnie W., et al.
Publicado: (2019)

Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
por: Gold, Laura S, et al.
Publicado: (2019)

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
por: Fleischmann, Roy, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH(1‐24) Depot and Methylprednisolone in Healthy Subjects
por: Poola, Nagaraju, et al.
Publicado: (2021)

Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review
por: Girman, Cynthia, et al.
Publicado: (2022)

A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020
por: Murayama, Anju, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i92j6bhk07ol71jdc2nqa90d4u